Histidine

Histidine

SCHEMBL6801012

CCC(C)C(N)C(N)=O.NC(Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP1A2 P05177 1/20 0.35
GRIA4 P48058 8/20 0.34
GRIA1 P42261 7/20 0.34
GRIA2 P42262 7/20 0.34
GRIA3 P42263 7/20 0.34
GRIK1 P39086 3/20 0.34
GRIK2 Q13002 3/20 0.34
GRIK3 Q13003 3/20 0.34
GRIK4 Q16099 3/20 0.34
GRIK5 Q16478 3/20 0.34
ALPI P09923 1/20 0.32
PKM P14618 1/20 0.32
PTGS1 P23219 1/20 0.32
XIAP P98170 1/20 0.32
CIT O14578 1/20 0.32
DPP8 Q6V1X1 3/20 0.31
DPP9 Q86TI2 3/20 0.31
DPP4 P27487 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL6801013 1.00 SLC7A5 (0.36) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL183768 0.92 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL183769 0.92 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL14940945 0.92 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL2024731 0.89 SLC7A5 (0.37) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL6803051 0.88 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL6803056 0.88 SLC7A5 (0.38) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL1528035 0.88 SLC7A5 (0.35) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL1528037 0.88 SLC7A5 (0.35) SLC7A5CYP3A4CYP1A2GRIA4GRIA1
Histidine SCHEMBL27580772 0.88 SLC7A5 (0.35) SLC7A5CYP3A4CYP1A2GRIA4GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358485-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2003-11-05 EP claimed
WO-2002035240-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2002-05-02 WO claimed
US-20040176298-A1 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors THE PROCTER & GAMBLE COMPANY (US) 2004-09-09 US disclosed
US-6750194-B1 ADMINISTERING TO THE SUBJECT A SAFE AND EFFECTIVE AMOUNT OF A VPAC RECEPTOR AGONIST SELECTED FROM THE GROUP CONSISTING OF RO 25-1553, AND PACAP-38 THE PROCTER & GAMBLE COMPANY 2004-06-15 US disclosed
EP-1358485-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2003-11-05 EP disclosed
WO-2002035240-A2 METHODS FOR IDENTIFYING COMPOUNDS FOR REGULATING MUSCLE MASS OR FUNCTION USING VASOACTIVE INTESTINAL PEPTIDE RECEPTORS THE PROCTER & GAMBLE COMPANY (US) 2002-05-02 WO disclosed
EP-1068347-A1 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS Millennium Pharmaceuticals, Inc. (US) 2001-01-17 EP disclosed
WO-1999051762-A9 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS MILLENNIUM PHARM INC (US) 2000-05-25 WO disclosed
WO-1999051762-A1 METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS MILLENNIUM PHARMACEUTICALS, INC. (US) 1999-10-14 WO disclosed
US-5217953-A Administering polypeptide to mammals to inhibit vip effect on sexual behavior and the growth of lung cancer cells THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 1993-06-08 US disclosed